Literature DB >> 22576872

An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid.

Gunnar Brinkmalm1, Erik Portelius, Annika Öhrfelt, Niklas Mattsson, Rita Persson, Mikael K Gustavsson, Charles H Vite, Johan Gobom, Jan-Eric Månsson, Jonas Nilsson, Adnan Halim, Göran Larson, Ulla Rüetschi, Henrik Zetterberg, Kaj Blennow, Ann Brinkmalm.   

Abstract

Amyloid precursor protein (APP) is the precursor protein to amyloid β (Aβ), the main constituent of senile plaques in Alzheimer's disease (AD). Endogenous Aβ peptides reflect the APP processing, and greater knowledge of different APP degradation pathways is important to understand the mechanism underlying AD pathology. When one analyzes longer Aβ peptides by low-energy collision-induced dissociation tandem mass spectrometry (MS/MS), mainly long b-fragments are observed, limiting the possibility to determine variations such as amino acid variants or post-translational modifications (PTMs) within the N-terminal half of the peptide. However, by using electron capture dissociation (ECD), we obtained a more comprehensive sequence coverage for several APP/Aβ peptide species, thus enabling a deeper characterization of possible variants and PTMs. Abnormal APP/Aβ processing has also been described in the lysosomal storage disease Niemann-Pick type C and the major large animal used for studying this disease is cat. By ECD MS/MS, a substitution of Asp7 → Glu in cat Aβ was identified. Further, sialylated core 1 like O-glycans at Tyr10, recently discovered in human Aβ (a previously unknown glycosylation type), were identified also in cat cerebrospinal fluid (CSF). It is therefore likely that this unusual type of glycosylation is common for (at least) species belonging to the magnorder Boreoeutheria. We here describe a detailed characterization of endogenous APP/Aβ peptide species in CSF by using an online top-down MS-based method.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22576872     DOI: 10.1002/jms.2987

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  28 in total

1.  The aqueous phase of Alzheimer's disease brain contains assemblies built from ∼4 and ∼7 kDa Aβ species.

Authors:  Jessica M Mc Donald; Tiernan T O'Malley; Wen Liu; Alexandra J Mably; Gunnar Brinkmalm; Erik Portelius; William M Wittbold; Matthew P Frosch; Dominic M Walsh
Journal:  Alzheimers Dement       Date:  2015-04-04       Impact factor: 21.566

2.  Amyloid-β metabolism in Niemann-Pick C disease models and patients.

Authors:  Niklas Mattsson; Maria Olsson; Mikael K Gustavsson; Marko Kosicek; Martina Malnar; Jan-Eric Månsson; Maria Blomqvist; Johan Gobom; Ulf Andreasson; Gunnar Brinkmalm; Charles Vite; Silva Hecimovic; Caroline Hastings; Kaj Blennow; Henrik Zetterberg; Erik Portelius
Journal:  Metab Brain Dis       Date:  2012-09-01       Impact factor: 3.584

Review 3.  Glycation vs. glycosylation: a tale of two different chemistries and biology in Alzheimer's disease.

Authors:  Naoyuki Taniguchi; Motoko Takahashi; Yasuhiko Kizuka; Shinobu Kitazume; Vladimir V Shuvaev; Tomomi Ookawara; Akiko Furuta
Journal:  Glycoconj J       Date:  2016-06-21       Impact factor: 2.916

4.  Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer's brain.

Authors:  Gunnar Brinkmalm; Wei Hong; Zemin Wang; Wen Liu; Tiernan T O'Malley; Xin Sun; Matthew P Frosch; Dennis J Selkoe; Erik Portelius; Henrik Zetterberg; Kaj Blennow; Dominic M Walsh
Journal:  Brain       Date:  2019-05-01       Impact factor: 13.501

5.  Isolation and characterization of glycosylated neuropeptides.

Authors:  Yang Liu; Qinjingwen Cao; Lingjun Li
Journal:  Methods Enzymol       Date:  2019-08-12       Impact factor: 1.600

6.  The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview.

Authors:  Angela L Jefferson; Katherine A Gifford; Lealani Mae Y Acosta; Susan P Bell; Manus J Donahue; L Taylor Davis; JoAnn Gottlieb; Deepak K Gupta; Timothy J Hohman; Elizabeth M Lane; David J Libon; Lisa A Mendes; Kevin Niswender; Kimberly R Pechman; Swati Rane; Frederick L Ruberg; Yan Ru Su; Henrik Zetterberg; Dandan Liu
Journal:  J Alzheimers Dis       Date:  2016-03-08       Impact factor: 4.472

7.  Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease.

Authors:  Charles H Vite; Jessica H Bagel; Gary P Swain; Maria Prociuk; Tracey U Sikora; Veronika M Stein; Patricia O'Donnell; Therese Ruane; Sarah Ward; Alexandra Crooks; Su Li; Elizabeth Mauldin; Susan Stellar; Marc De Meulder; Mark L Kao; Daniel S Ory; Cristin Davidson; Marie T Vanier; Steven U Walkley
Journal:  Sci Transl Med       Date:  2015-02-25       Impact factor: 17.956

8.  Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases.

Authors:  Magdalena Nutu; Philippe Bourgeois; Henrik Zetterberg; Erik Portelius; Ulf Andreasson; Stéphane Parent; Francesco Lipari; Sara Hall; Radu Constantinescu; Oskar Hansson; Kaj Blennow
Journal:  Neuromolecular Med       Date:  2012-12-07       Impact factor: 3.843

Review 9.  Protein post-translational modifications and misfolding: new concepts in heart failure.

Authors:  Federica Del Monte; Giulio Agnetti
Journal:  Proteomics Clin Appl       Date:  2014-08       Impact factor: 3.494

10.  Targeting synaptic pathology with a novel affinity mass spectrometry approach.

Authors:  Ann Brinkmalm; Gunnar Brinkmalm; William G Honer; Julie A Moreno; Joel Jakobsson; Giovanna R Mallucci; Henrik Zetterberg; Kaj Blennow; Annika Öhrfelt
Journal:  Mol Cell Proteomics       Date:  2014-06-27       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.